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Abstract: Locally advanced pancreatic carcinoma (LAPC) has a poor prognosis and the purpose 
of treatment is survival prolongation and symptom palliation. Radiotherapy has been reported 
to reduce pain in LAPC. Stereotactic RT (SBRT) is considered as an emerging radiotherapy 
technique able to achieve high local control rates with acceptable toxicity. However, its role in 
pain palliation is not clear. To review the impact on pain relief with SBRT in LAPC patients, 
a literature search was performed on PubMed, Scopus, and Embase (January 2000–December 
2017) for prospective and retrospective articles published in English. Fourteen studies (479 
patients) reporting the effect of SBRT on pain relief were finally included in this analysis. SBRT 
was delivered with both standard and/or robotic linear accelerators. The median prescribed SBRT 
doses ranged from 16.5 to 45 Gy (median: 27.8 Gy), and the number of fractions ranged from 
1 to 6 (median: 3.5). Twelve of the 14 studies reported the percentage of pain relief (in patients 
with pain at presentation) with a global overall response rate (complete and partial response) 
of 84.9% (95% CI, 75.8%–91.5%), with high heterogeneity (Q2 test: P<0.001; I2=83.63%). All 
studies reported toxicity data. Acute and late toxicity (grade ≥3) rates were 3.3%–18.0% and 
6.0%–8.2%, respectively. Reported gastrointestinal side effects were duodenal obstruction/
ulcer, small bowel obstruction, duodenal bleeding, hemorrhage, and gastric perforation. SBRT 
achieves pain relief in most patients with pancreatic cancer with an acceptable gastrointestinal 
toxicity rate. Further prospective studies are needed to define optimal dose/fractionation and 
the best systemic therapies modality integration to reduce toxicity and improve the palliative 
outcome. Finally, the quality of life and, particularly, pain control should be considered as an 
endpoint in all future trials on this emerging treatment technique.
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Introduction
Locally advanced pancreatic carcinoma (LAPC) is a lethal disease associated with 
multiple debilitating symptoms and 38.7%–49.1% rates of 1-year survival.1 Moreover, 
quality of life (QoL) is poor because of several symptoms such as jaundice, weight loss, 
obstruction, and, particularly, pain. The latter is very frequent because of pancreatic 
tissue innervation by networks interacting with both the sympathetic and parasympa-
thetic systems yielding to increased sensitivity. Therefore, pain relief is a major goal 
of palliative treatment in patients with LAPC.2
Radiotherapy (RT) has been used as a noninvasive treatment in the management 
of these patients to achieve local control and pain relief. Particularly, prolonged (5–6 
weeks) concurrent chemoradiation has been considered as a treatment option in LAPC. 
However, this combined modality treatment may produce discomfort in these patients 
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with poor performance status due to treatment duration and 
not negligible toxicity.
Stereotactic RT (SBRT) is an emerging treatment tech-
nique for LAPC patients due to several factors such as the 
possibility to deliver high biological doses to the tumor 
because of the lower irradiation of organs at risk.3 Further-
more, due to the short treatment duration, SBRT produces 
less discomfort to the patients and can be easily combined 
with standard chemotherapy. Based on the reported efficacy 
in terms of local control, SBRT has the theoretical potential 
to relieve pain in LAPC patients. However, this issue has 
never been systematically analyzed in prospective studies 
or meta-analyses.
Therefore, the aim of this study is to systematically 
review the available evidences on pain control after SBRT 
in patients with LAPC.
Materials and methods
A systematic search in the electronic databases of PubMed, 
Embase, and Scopus (January 2000–December 2017) for 
full-text published studies on SBRT in pancreatic cancer 
(PC) was performed. Only studies published in English 
were included in this review. Prospective and retrospective 
studies on LAPC treated with SBRT and reporting on pain 
control were included in the review. Case reports, review 
articles, and published conference abstracts were excluded. 
The following search strategy was used in PubMed database: 
(“pancreatic neoplasms” [MeSH Terms]) OR (“pancreatic” 
[All Fields] AND “neoplasms” [All Fields]) OR “pancreatic 
neoplasms” [All Fields] OR (“pancreatic” [All Fields] AND 
“cancer” [All Fields]) OR (“pancreatic cancer” [All Fields]) 
AND (“radiotherapy” [Subheading] OR “radiotherapy” [All 
Fields] OR “radiotherapy” [MeSH Terms]) AND (“pain” 
[MeSH Terms] OR “pain” [All Fields]).
Two independent authors (MB, GM) screened citations 
at the title and abstract level to identify potentially relevant 
studies without any duplication. Potentially eligible citations 
were retrieved for full-text review and any uncertainty was 
resolved by another author (AGM). The following informa-
tion was extracted from each study: year of publication, 
study design, inclusion criteria, total number of patients and 
number of patients with pain, stage, irradiation technique, 
planning target volume (PTV) definition, dose prescription, 
median RT dose, median biologically equivalent doses in 2 
Gy fractions (EQD
2
; α/β: 3 and 10), percentage of patients 
receiving chemotherapy, pain response rate and evaluation 
criteria, pain-free survival, and toxicity. The median EQD
2
 
was calculated from the prescribed tumor doses by using 
an α/β value of 3 Gy for late effects and 10 Gy for tumor 
effects.
Outcome measures
The main outcome measure was pain relief evaluated by 
reduction of analgesic administration, suspension of analge-
sic administration, and partial response (PR) and complete 
response (CR). Secondary outcome measures were toxicity 
and pain-free survival.
Statistical analysis
Proportions and rates were pooled by means of a random-
effects model in case of heterogeneity across studies; 
otherwise, a fixed-effect model was used. The dependent 
variables were modeled on the logit (log-odds) scale, con-
verted back to percentages, and then presented as point 
estimates and 95% CI. Statistical heterogeneity was quan-
tified with the I2 statistic (high heterogeneity level: >50%) 
and tested using the Q2 test (statistical significance level: 
P<0.1). All tests were two-sided, and statistical significance 
was taken as P<0.05, except when investigating heteroge-
neity across studies, in which case it was taken as P<0.10. 




From a total of 231 retrieved publications, after applying 
the selection criteria, 14 studies were found suitable for the 
analysis (Figure 1).4–17
The design of the analyzed papers was prospective in 
seven studies and retrospective in the other seven stud-
ies. According to the extracted data, different scenarios of 
advanced disease were included (LAPC with or without 
metastatic disease and locally recurrent PC both after surgery 
and/or RT). From a total of 469 patients, 190 patients reported 
with pain before SBRT treatment in 12 studies.4–7,9–12,14–17 
Two studies8,13 did not report the number of patients with 
pain before SBRT.
Literature review
Hoyer et al treated 22 patients using a standard linear accel-
erator (LINAC) and delivering 45 Gy in three fractions 
(EDQ
2
: 93.8 Gy) to a PTV defined as the gross tumor volume 
(GTV) plus edema plus 5–10 mm margin. Chemotherapy was 
not used, and no pain response was recorded. The authors 
reported increased pain 2 weeks after treatment and 22.5% 
of patients experiencing severe gastrointestinal (GI) toxicity.4
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Seo et al treated 30 patients with T4 stage (N1: 30%) in 
a Phase I dose escalation study using a robotic LINAC. A 
single SBRT fraction dose between 14 and 17 Gy (median: 
16.5 Gy; EDQ
2
: 76.4 Gy) was delivered to the PTV (GTV 
+2–4 mm) as a boost after conformal RT. Seventy percent 
of patients received induction or adjuvant chemotherapy and 
55.6% of patients reported reduced analgesic consumption 
(RAA).5
Didolkar et al treated 85 LAPC patients (24.5% of them 
also had distant metastases) using a robotic device to deliver 
a dose between 15 and 30 Gy (median: 25.5 Gy) in three 
fractions (median EDQ
2
: 39.3 Gy) to the PTV (GTV +3 
mm). Chemotherapy was administered to 100% of patients 
after SBRT. The authors reported 48.4% CR and 51.6% PR 
using a 0–10 scale, 18–24 weeks pain-free survival, and late 
toxicity (hemorrhage/obstruction) in 8.2% patients.6
Shen et al treated 20 LAPC patients using a robotic 
LINAC to deliver 32–55 Gy (median: 45 Gy; EDQ
2
: 79.7 
Gy) in three to six fractions (median: 4) to the PTV (GTV 
+3–5 mm). Chemotherapy was not administered. The authors 
reported 90% pain relief using a visual analog scale (VAS).7
Polistina et al treated 23 patients with LAPC and <6 cm 
maximum tumor size using a robotic device to deliver 30 
Gy in three fractions (EDQ
2
: 50.0 Gy). Both induction and 
adjuvant chemotherapy were administered in all patients 
before and after SBRT. The authors did not report significant 
reduction in pain response using a VAS scale.8
Rwigema et al treated 71 patients (LAPC: 56; recurrence: 
16; metastatic disease: 11; residual disease after surgery: 
17) using a standard or robotic LINAC to deliver a single 
fraction of 18–25 Gy (median: 24; EDQ
2
: 68.0 Gy) to the 
PTV (GTV +2 mm). Ninety percent of patients received 
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Figure 1 Flow diagram of study identification and selection.





both induction and adjuvant chemotherapy. The authors 
reported 81.3% CR.9
Macchia et al treated 16 PC patients (cT4: 87.5%, local 
recurrence: 12.5%) using a standard LINAC to deliver 20–35 
Gy (median: 25 Gy; EDQ
2
: 31.3 Gy) in five fractions pre-
scribed to the PTV (GTV +≥10 mm). All patients received 
chemotherapy before SBRT. The authors reported CR, PR, 
and RAA as 25.0%, 31.3%, and 40.0%, respectively. Late tox-
icity (duodenal bleeding) was recorded in 6.2% of patients.10
Wild et al treated 18 patients with LAPC or recurrent 
disease using a standard LINAC to deliver 20–27 Gy (median: 
25 Gy; EDQ
2
: 31.3 Gy) in five fractions to the PTV (internal 
target volume +1–3 mm). Chemotherapy was administered 
to 28.0% of patients after SBRT. The authors reported 57.0% 
“effective palliation” and 6.0% late small bowel obstruction.11
Tozzi et al treated 30 patients with LAPC or recurrent 
disease using a standard LINAC to deliver 45 Gy in six 
fractions (EDQ
2
: 65.5 Gy) to the PTV (GTV +5–10 mm). 
Chemotherapy was administered before SBRT to all patients. 
The authors reported suspension of analgesic administration 
(SAA) and RAA in 63.6% and 36.4% of patients, respec-
tively, using a Numerical Rating Scale (NRS).12
Herman et al treated 49 LAPC patients using a standard 
LINAC to deliver 33 Gy in five fractions (EDQ
2
: 45.7 Gy) 
to the PTV (GTV +2–3 mm). Induction chemotherapy was 
administered to 90.0% of patients and adjuvant chemotherapy 
to all patients after SBRT. The authors reported a reduction of 
8 points of pain from baseline (25 points) using the quality of 
life questionnaire for patients with pancreatic cancer (QLQ-
PAN 26) scoring system. GI late toxicity rate was 6.4%.13
Su et al treated 25 patients with LAPC or metastatic 
disease using a robotic LINAC to deliver 36 Gy in three frac-
tions (EDQ
2
: 66.0 Gy) or 30–48 Gy in three to four fractions 
to the PTV (GTV +1–2 mm). Both induction and adjuvant 
chemotherapy were used in 8.0% of patients before and after 
SBRT. The authors reported 50.0% and 15.0% SAA and RAA 
rates, respectively, using an NRS scale.14
Kim et al treated 26 not operable patients using a stan-
dard or robotic LINAC to deliver a median dose of 24 Gy 
(range: 24–36 Gy) in one to three fractions (median EDQ
2
: 
68.0 Gy) to the PTV (GTV +2 mm). Induction and adjuvant 
chemotherapy were used in 15.0% and 23.0% of patients, 
respectively. The authors reported SAA in 35.7% of patients.15
Comito et al treated 31 patients with isolated recurrent dis-
ease using a Flattening Filter Free Rapidarc technique to deliver 
45 Gy in six fractions (EDQ
2
: 65.5 Gy) to the PTV (GTV +5–7 
mm). Induction and adjuvant chemotherapy was administered 
in 20.0% and 77.0% of patients before and after SBRT, respec-
tively. The authors reported SAA and RAA in 58.0% and 40.0% 
of patients, respectively, using an NRS scale.16
Koong et al treated 23 previously irradiated patients 
with local recurrences using a standard or robotic LINAC to 
deliver 25 Gy in five fractions (EDQ
2
: 31.3 Gy) to the PTV 
(internal target volume +2–3 mm). Induction chemotherapy 
was delivered in 26.1% of patients. The authors reported 
“pain improvement” in 57.1% of patients.17
Patients’ clinical stage was not reported in nine stud-
ies.6,8,11–14,16,17 In one study, 100% of patients had cT4 tumor 
stage,5 while in another trial, this rate was 87.5%.10 In two 
studies only, patients with stage II–IV were enrolled7,15 and 
in another, all patients had T1–3 N0 M0 PC.4
Different treatment devices were used including robotic 
LINACs (six reports),5–8,14,16 standard LINACs (five stud-
ies),4,10–13 and both (three papers).9,15,17
Thirteen studies reported the details of PTV definition: 
eleven studies used a 1–5 mm GTV/internal tumor volume 
to PTV margin,5–7,9,11–17 one study used a >10 mm GTV to 
PTV margin,10 and only Hoyer et al defined the PTV as the 
GTV plus edema plus 5–10 mm.4
Dose prescription, reported in 12 of 14 papers, was 
according to the International Commission on Radiation 
Units-62 in one study10 and to specific isodose lines ranging 
from 67% to 100% in eleven studies.4–7,9,11–16 The median 
prescribed SBRT doses ranged from 16.5 to 45 Gy (median: 
27.8 Gy), while the number of fractions ranged from 1 to 6 
(median: 3.5). The computed median EQD
2[α/β=10] ranged from 
31.3 to 93.8 Gy (median: 65.5 Gy) and the median EQD
2[α/
β=3] from 40.0 to 162.0 Gy (median: 95.0 Gy).
Twelve studies reported induction or adjuvant chemother-
apy regimens in patients ranging from 8.0% to 100.0%.5,6,8–17 
The characteristics and main results of these publications are 
reported in Table 1.
Pain relief
The pain response was scored using different scales: NRS in 
three studies,12,14,16 VAS in three studies,6–8 and QLQ-PAN-26 
in one study.13 Six studies did not report the assessment 
scale.4,5,10,11,15,17 Twelve of the 14 studies reported various rates 
of pain relief.5–7,9–17 Six studies5,10,12,14–16 reported 69.50% rates 
of RAA or SAA (95% CI, 59.49%–78.31%), with high het-
erogeneity between studies (Q2 test: P<0.0001; I2=86.44%) 
to describe pain relief after SBRT (Figure 2). Three stud-
ies reported 54.25% CR rates in 56 patients (95% CI, 
40.76%–67.29%), with high heterogeneity (Q2 test: P<0.013; 
I2=76.68%)9,5,8 (Figure 3). Overall global response rate to 
pain in terms of CR or PR as reported in 85 patients from 
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five studies was 84.9% (95% CI, 75.8%–91.5%), with high 
heterogeneity again (Q2 test: P<0.001; I2=83.63%),5,6,8,9,14,16 
as shown in Figure 4. Only one study6 reported pain-free 
survival ranging from 18 to 24 weeks. One study reported 
no significant pain reduction,8 while another study reported 
a significant worsening of pain 2 weeks after SBRT.4
Toxicity
All studies reported toxicity using the following scoring 
systems: Radiation Therapy Oncology Group in four stud-
ies,5,7,10,15 CTCAE in five studies,6,8,12,16,17 and WHO in one 
study,4 while four studies did not report the used scale.9,11,13,14 
Acute and late toxicity (grade ≥3) rates were 3.3%–18.0% and 
6.0%–8.2%, respectively. Reported gastrointestinal complica-
tions were duodenal obstruction/ulcer, small bowel obstruc-
tion, duodenal bleeding, hemorrhage, and gastric perforation.
Discussion
We performed a systematic review to analyze the impact of 
SBRT on pain control in patients with PC. Our analysis has 
several limitations. Overall, only few studies that reported 
on pain control were included in the analysis. Secondly, only 
4/14 studies had a prospective design, and are therefore more 
credible in the evaluation of results. Furthermore, in eleven 
studies, the number of patients with pain before treatment was 
<20. Inclusion criteria were inconsistent, with some studies 
including only primary tumors and others also including local 
recurrences. Treatment techniques were uneven in terms of 
target definition, dose and fractionation, and dose prescrip-
tion. In addition, percentages of patients who underwent 
chemotherapy were variable between the different studies. 
Finally, criteria and methods for assessing pain and toxicity 
were widely variable in the analyzed papers.
Another limitation of our study is the lack of a system-
atic evaluation of the quality of the analyzed studies and, in 
particular, the risk of bias. However, having clearly observed 
that no study considered pain palliation as a primary objec-
tive and that the description of this endpoint was reported 
in all the studies in a synthetic and not systematic way, it is 
obvious that for the purposes of our analysis, all the studies 
have a low-level quality.
However, despite these limitations, most studies reported 
pain improvement after SBRT. Only two studies reported no 
changes8 or pain worsening.4 Nevertheless, it should be noted 
that in the first study, the comparison between VAS before and 
after SBRT was performed in all treated patients, without any 
separate analysis on the group with pain before treatment.8 
Obviously, this limitation could have reduced the possibility 
to detect a significant improvement of pain. The second study 
was the one delivering the highest EQD
2
 (using α/β values of 
3 and 10) from all the analyzed series.4 Furthermore, the PTV 
was defined with larger margins compared to those reported 
in all other studies (GTV+surrounding edema+5–10 mm). 
This is probably the reason of the high GI complications 
rate (grade ≥3: 22.5%) and of increased pain due to gastric-
duodenal ulcerations.4
Except for these two studies, in all other reports, a reduc-
tion in pain was achieved, in most cases exceeding 50% of 
patients. The variability of symptomatic response evaluation 
hinders the analysis of dose and pain response relationship. 
However, it could be noted that considering the studies report-
ing the pain CR rate, this value was <50% in two studies with 
31.3 and 39.3 Gy median EDQ
2[α/β=10]
6,10 and was 81.3% in a 
study with 68.0 Gy median EDQ
2[α/β=10].
9
In some studies, cases of severe GI toxicity were recorded. 
The prevention of toxicity should be pursued to avoid worsen-
ing of QoL in these patients with generally poor performance 
status.18,19
Trying to correlate the EQD
2[α/β=3] with late toxicity, no 
clear threshold between delivered dose and long-term side 
effects was observed. In fact, in some series with low (40 Gy) 
EQD
2[α/β= 3], both late bleeding
10 and bowel obstruction11 were 
reported, while in most series with high (104.4–129.6 Gy) 
EQD
2[α/β=3], no cases of late toxicity were observed.
5,7,9,14,15
More specifically, in the studies reporting cases of late 
toxicity,4,6,10,11,13 the median EQD
2
(α/β: 3) was 58.6 Gy 
(range: 40.0–162.0 Gy), while in the studies not reporting 
late toxicity,5,7–9,12,14–17 the median value was 104.4 Gy (range: 
40.0–135.0 Gy). On the basis of these paradoxical data, it is 
difficult to identify a correlation between dose and toxicity. 
If we consider the series in which >50% of patients received 
chemotherapy,5,6,8–10,12,13,16 three out of eight studies reported 
late toxicity (37.5%). Instead, if we consider studies in which 
<50% of patients received chemotherapy,11,14,15,17 only one-
fourth reported late toxicity (25%). This is evidently a modest 
difference that does not allow us to establish a clear correla-
tion between chemotherapy and radiation-induced toxicity. 
Instead, considering the studies reporting the maximum 
GTV to PTV radial margin, we observed that the median 
value was 6.5 mm (range: 3–10 mm) in the studies with 
late toxicity4,6,10,13 and 2 mm (range: 2–7 mm) in the studies 
without late toxicity.5,7,9,12,14–16 From this simple qualitative 
assessment, the width of the GTV–PTV margins seems to 
be the parameter most correlated to toxicity.
The results of our study in terms of the relationship 
between toxicity and dose are different compared to those of 





Table 1 Characteristics and outcomes of analyzed studies
Author, 
year





Stage Technique PTV Dose 
prescription








% of patients 
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chemotherapya





Grade 3–4 toxicity %
(scale)
Hoyer et al, 
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45 Gy in three 
fractions










Seo et al, 
20095

























NR Acute: duodenal 












RSBRT GTv+3 mm To 80% 
isodose
25.5 Gy in three 
fractions (15–30)





Acute: duodenitis (14.1) 




Shen et al, 
20107




RSBRT GTv+3–5 mm v75%>95% 45 Gy (32–55) in four 
(3–6) fractions











RSBRT NR NR 30 Gy in three 
fractions













RRS or LiNAC GTv+2 mm To 80%–89% 
isodose
24 Gy SF (18–25) 68.0 129.6 90a and/or after CR: 81.3
(NR)













GTv+≥10 mm iCRU-62 25 Gy in five fractions 
(20–35)





Late: duodenal bleeding: 
6.2
(RTOG)
wild et al, 
201311









SBRT iTv+1–3 mm To isodose 
surrounding 
PTv
25 Gy in five fractions 
(20–27)




Late: small bowel 
obstruction: 6.0
(NR)
Tozzi et al, 
201312











45 Gy in six fractions 
(36–45)








Phase ii LA 49
(NR)
NR SBRT (vMAT) GTv+2–3 mm v100%>90% 33 Gy in five fractions 45.7 63.4 90
a
100 after
Reduction of 8 points from 
baseline: 25 points
(QLQ-PAN 26)
NR Acute: duodenal ulcer: 
2.0g; late: duodenal 
ulcer/bleeding: 6.4
(NR)
Su et al, 
201514




RSBRT GTv+1–2 mm v93%>97 36 Gy in three 
fractions (30–48 in 


















LiNAC or RRS 
or RSBRT
GTv+2 mm To 80%–93% 
isodose




















iTv+5 mm or 
GTv+5–7 mm
To mean PTv 
dose



















iTv+2–3 mm NR 25 Gy in five fractions 31.3 40.0 26.1a “Relative improvement” 57.1
(NR)
NR Acute: Gi (8.7); late: 0.0
(CTCAe v. 4.0)
Notes: ainduction. bOf 12 patients evaluated at 3 months, 50% had “less pain”. cPrevious RT: 34.1%. dOnly patients with moderate/severe pain. ePrior RT: 21%. fTen patients 
received SBRT as a boost after chemoradiation. gelevated aspartate/alanine aminotransferase: 10%.
Abbreviations: 3D-CRT, 3D-conformal radiation therapy; CC, cranio-caudally; CR, complete response; CTCAe, Common Terminology Criteria for Adverse events; CTC, 
Common Toxicity Criteria; CTv, clinical target volume; eORTC, european Organization for Research and Treatment of Cancer; eQD2, biologically equivalent doses in 2 Gy 
fractions; FFF, filter flattering free; GI, gastrointestinal; GTV, gross tumor volume; ICRU, International Commission on Radiation Units; ITV, internal tumor volume; LA, locally 
advanced; LiNAC, linear accelerator; M, metastases; NA, not administered; N, nodes; NR, not reported; NRS, Numerical Rating Scale; PR, partial response; PTv, planning 
target volume; RAA, reduction of analgesic administration; Rec, recurrence; RRS, robotic radiosurgery; RSBRT, stereotactic radiosurgery; RT, radiation therapy; RTOG, 
Radiation Therapy Oncology Group; SAA, suspension of analgesic administration; SBRT, stereotactic RT; SF, single fraction; vAS, visual analog scale; vMAT, volumetric 
modulated arc therapy; wHO, world Health Organization.
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Abbreviations: 3D-CRT, 3D-conformal radiation therapy; CC, cranio-caudally; CR, complete response; CTCAe, Common Terminology Criteria for Adverse events; CTC, 
Common Toxicity Criteria; CTv, clinical target volume; eORTC, european Organization for Research and Treatment of Cancer; eQD2, biologically equivalent doses in 2 Gy 
fractions; FFF, filter flattering free; GI, gastrointestinal; GTV, gross tumor volume; ICRU, International Commission on Radiation Units; ITV, internal tumor volume; LA, locally 
advanced; LiNAC, linear accelerator; M, metastases; NA, not administered; N, nodes; NR, not reported; NRS, Numerical Rating Scale; PR, partial response; PTv, planning 
target volume; RAA, reduction of analgesic administration; Rec, recurrence; RRS, robotic radiosurgery; RSBRT, stereotactic radiosurgery; RT, radiation therapy; RTOG, 
Radiation Therapy Oncology Group; SAA, suspension of analgesic administration; SBRT, stereotactic RT; SF, single fraction; vAS, visual analog scale; vMAT, volumetric 
modulated arc therapy; wHO, world Health Organization.





Figure 4 Overall global response to pain.
Notes: Based on five studies (85 patients), the global response rate to pain in terms of complete and partial response rate was 84.9% (95% CI, 75.8%–91.6%), with high 
heterogeneity (Q2 test: P<0.001; I2=83.63%).
Abbreviation: df, degrees of freedom.
Figure 2 Overall response rate to analgesic administration in terms of reduction and suspension of analgesic therapy.
Notes: Based on six studies (94 patients), the overall response rate to analgesic administration in terms of reduction or suspension of analgesic therapy was 69.5% (95% Ci, 
59.5%–78.3%), with high heterogeneity between studies (Q2 test: P<0.0001; I2=86.44%).
Abbreviation: df, degrees of freedom.
Figure 3 Overall complete response to pain.
Notes: Based on three studies (56 patients), the overall complete response rate to pain was 54.2% (95% Ci, 40.8%–67.3%), with high heterogeneity (Q2 test: P<0.013; 
I2=76.68%).
Abbreviation: df, degrees of freedom.
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Brunner et al,18 but the different methods of analysis and the 
selection criteria should be considered. In fact, in our analy-
sis, only studies reporting data on pain relief were included.
The efficacy of RT in pain relief in this setting is not new. 
Patients with LAPC treated with standard chemoradiation 
experienced pain reduction (in 35%–65% of cases).20 How-
ever, the rate of toxicity recorded in SBRT series seems lower 
compared to standard radio-chemotherapy. In fact, rates of 
36%–79% grade 3–4 toxicity and 41% of grade 4–5 toxic-
ity were reported in concurrent chemoradiation studies.21–23 
Furthermore, the survival outcome recorded in series of 
chemoradiation and SBRT seems relatively similar.24
Also, chemotherapy alone can reduce pain in patients 
with LAPC.25 Therefore, it could be interesting to compare 
the palliation results of chemotherapy with the ones of 
SBRT or to evaluate the efficacy in terms of pain relief by 
combining the two treatments. Unfortunately, our analysis 
is not able to provide indications on these topics because 
in most series, both SBRT and chemotherapy were admin-
istered, and therefore, we cannot compare the two treat-
ments. Furthermore, it is difficult to evaluate the efficacy 
of combining the two treatments because pain response was 
evaluated comparing the intensity of this symptom before 
and after SBRT and not before and after the whole treatment 
(SBRT+chemotherapy).
Other ablative therapies have been proposed in the treat-
ment of LAPC, such as radiofrequency ablation, irreversible 
electroporation, high-intensity focused ultrasound, iodine 
125, cryosurgery, photodynamic therapy, and microwave 
ablation. A literature review reported the possibility to reduce 
pain with some of these treatments such as radiofrequency 
ablation, irreversible electroporation, SBRT, and high-inten-
sity focused ultrasound. However, among these treatments, 
SBRT was found to be the only procedure without related 
mortality and with proven efficacy in QoL improvement.26
Based on the results of this analysis, SBRT can be con-
sidered as an option in the treatment of symptomatic patients 
with LAPC. However, a high level of accuracy is required 
in treatment planning and delivery to reduce the risk of GI 
complications. Guidelines are available in literature to mini-
mize the probability of side effects.18,19 Furthermore, more 
sophisticated and advanced techniques are now available 
to improve precision in SBRT delivery, such as intensity-
modulated RT,27 simultaneous integrated boost,3,28 respiratory 
gating,29 and adaptive re-planning.30
In conclusion, SBRT achieves pain relief in most patients 
with PC. Furthermore, late toxicity was recorded in only a 
minority of studies and, even in these, with an incidence of 
<10%. Therefore, the recorded toxicity can be considered 
acceptable. Further prospective studies on the palliative 
role of SBRT in LAPC are needed to define the optimal 
dose/fractionation and the best systemic therapies modality 
integration with the aim to reduce toxicity and improve the 
palliative outcome. Finally, QoL and, particularly, pain con-
trol should be considered as an endpoint in all future trials 
on this emerging treatment technique.
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